Advertisement


Xin Gao, MD, on Advanced or Metastatic Urothelial Carcinoma: LY4101174

ASCO 2026

Advertisement

Xin Gao, MD, of Massachusetts General Hospital and Harvard Medical School, discusses initial results from the phase I EXCEED trial of LY4101174, a Nectin-4–targeting antibody-drug conjugate, for patients with advanced or metastatic urothelial carcinoma (Abstract 4517).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
This is a clinical trial that was performed as a dose-escalation study in patients with advanced metastatic urothelial carcinoma as well as other solid tumors known to express Nectin-4. The background for this study is that we know that enfortumab vedotin and pembrolizumab have really revolutionized the treatment for patients with advanced and metastatic urothelial cancers. But unfortunately, treatment resistance and treatment intolerability become an issue. Patients do need additional treatments beyond EV plus pembrolizumab, and unfortunately, at this time, the standard of care remains unclear and prognosis remains poor for patients who need another therapy beyond EV and pembrolizumab. We conducted this phase 1 clinical trial with a dose-escalation design. Eighty-six patients in total had metastatic urothelial cancers, and we looked at various dose levels, starting with low doses, Q2-week dosing as well as Q3-week dosing, which was explored after patients developed DLTs at the third dose level of Q2-week dosing. The vast majority of patients were heavily pretreated patients. Median lines of prior therapy was 3; 88% of patients had received prior platinum-based chemotherapy, 92% had received prior enfortumab vedotin, and all patients had received prior immune checkpoint inhibitors. So I think this was a study that really captured, you know, what's going on in the real world when patients need to think about another therapy beyond EV plus pembrolizumab and platinum-based chemotherapy. What we saw was that there was antitumor activity, particularly at the highest dose level of 4 mg/kg Q3-week dosing. We saw an objective response rate of 36% with the dose, with a disease control rate of 76%. However, we also ran into dose-limiting and significant hematologic toxicities, including grade 3 or higher anemia, neutropenia, thrombocytopenia, as well as febrile neutropenia at the highest dose level despite use of G-CSF prophylaxis. So the EXCEED study was a proof of concept that further targeting of Nectin-4 remains a viable and important clinical strategy for patients with treatment-refractory metastatic urothelial cancers after enfortumab vedotin. I think future work will be needed to continue to develop and study newer, other kinds of Nectin-4-targeting drugs with different payloads, different linkers, that hopefully will be able to find a dose that's both efficacious and tolerable for patients.

Related Videos

Skin Cancer

Katharina C. Kaehler, MD, on Daromun in Resectable Locally Advanced Melanoma: Trial Updates

Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional therapy in patients with resectable, locally advanced stage III melanoma (Abstract LBA9517). 

Shubham Pant, MD, MBBS, on Novel RAS-Targeting Therapy Daraxonrasib Doubles Overall Survival in Metastatic Pancreatic Cancer

Shubham Pant, MD, MBBS, of The University of Texas MD Anderson Cancer Center, discusses the practice-changing results of the phase III RASolute 302 study, which showed that daraxonrasib doubled median overall survival compared with standard chemotherapy in pretreated metastatic pancreatic cancer (Abstract LBA5).  

Lung Cancer

Julie R. Brahmer, MD, FASCO, on Previously Untreated Advanced Squamous NSCLC: HARMONi-6 Trial

Julie R. Brahmer, MD, FASCO, of the Bloomberg–Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, provides expert commentary on the overall survival results from the phase III HARMONi-6 trial presented in this year’s Plenary Session. The study compared ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy in previously untreated patients with advanced squamous non–small cell lung cancer (NSCLC) (Abstract LBA4).

Prostate Cancer

Adam Kibel, MD, on PROTEUS Trial in High-Risk Prostate Cancer: A Surgical Oncologist’s Perspective

Adam Kibel, MD, of Brigham and Women's Hospital, discusses findings from the phase III PROTEUS trial, which evaluated perioperative (neoadjuvant and adjuvant) apalutamide and androgen deprivation therapy vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer. Dr. Kibel talks about how the regimen of apalutamide and ADT affects both the surgical procedure itself as well as patient outcomes postprocedure (Abstract LBA1).

Gastrointestinal Cancer
Gastroesophageal Cancer

Yelena Y. Janjigian, MD, FASCO, on Safety Results From DESTINY-Gastric03

Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses safety results for DESTINY-Gastric03 Part 2 (arms D and F) and Part 4. The trial evaluated first-line fam-trastuzumab deruxtecan-nxki–based regimens in advanced HER2-expressing gastric cancer, gastroesophageal adenocarcinoma, and esophageal carcinoma (Abstract 4002).

Advertisement

Advertisement




Advertisement